Duarte-Jurado Ana Patricia, Gopar-Cuevas Yareth, Saucedo-Cardenas Odila, Loera-Arias Maria de Jesus, Montes-de-Oca-Luna Roberto, Garcia-Garcia Aracely, Rodriguez-Rocha Humberto
Departamento de Histología, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico.
Centro de Investigación Biomédica del Noreste, Departamento de Genética Molecular, Instituto Mexicano del Seguro Social, Delegación Nuevo León 40080, Mexico.
Antioxidants (Basel). 2021 Mar 15;10(3):453. doi: 10.3390/antiox10030453.
Oxidative stress is considered one of the pathological mechanisms that cause Parkinson's disease (PD), which has led to the investigation of several antioxidants molecules as a potential therapeutic treatment against the disease. Although preclinical studies have demonstrated the efficacy of these compounds to maintain neuronal survival and activity in PD models, these results have not been reflected in clinical trials, antioxidants have not been able to act as disease modifiers in terms of clinical symptoms. Translational medicine currently faces the challenge of redesigning clinical trials to standardize criteria when testing molecules to reduce responses' variability. Herein, we discuss current challenges and opportunities regarding several non-enzymatic antioxidants' therapeutic molecules for PD patients' potential treatment.
氧化应激被认为是导致帕金森病(PD)的病理机制之一,这促使人们对几种抗氧化剂分子进行研究,将其作为针对该疾病的潜在治疗方法。尽管临床前研究已证明这些化合物在PD模型中具有维持神经元存活和活性的功效,但这些结果并未在临床试验中得到体现,抗氧化剂在临床症状方面未能起到疾病修饰作用。转化医学目前面临着重新设计临床试验的挑战,以便在测试分子时规范标准,以减少反应的变异性。在此,我们讨论了几种非酶抗氧化剂治疗分子在PD患者潜在治疗方面当前面临的挑战和机遇。